Kayoko Shioda1, Cristiana M Toscano2, Maria Tereza Valenzuela3, William Valdez Huarcaya4, Joshua L Warren5, Daniel M Weinberger1, Lucia H de Oliveira6. 1. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA. 2. Department of Collective Health, Institute of Tropical Pathology and Public Health (IPTSP), Federal University of Goiás (UFG), Goiânia, Goiás, Brazil. 3. Department of Epidemiology and Public Health, Universidad de Los Andes, Santiago, Chile. 4. Universidad Peruana de Ciencias Aplicadas, Lima, Peru. 5. Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA. 6. Comprehensive Family Immunization Unit/FPL, Pan American Health Organization, World Health Organization, District of Columbia, USA.
Abstract
Background: Pneumococcal conjugate vaccines (PCVs) have prevented deaths due to pneumonia among children. The effect may differ between higher- and lower-income populations due to various factors, such as differences in the distribution of pneumococcal serotypes, healthcare access, and PCV uptake. This study aims to evaluate an association between increasing PCV coverage and population-level declines in death due to pneumonia and its variation by socioeconomic status of subnational regions. Methods: We analyzed municipality-level mortality data from 2005 and 2015 for children aged 2-23 months in Brazil, Colombia, and Peru. We fit Poisson regression models to estimate the relationship between changes in PCV uptake and deaths due to all-cause pneumonia among subnational regions with different income levels. We controlled for changes unrelated to PCV by using data on non-respiratory deaths over time. Results: Uptake of the third dose of PCV varied across subnational regions and was higher in high-income regions. Higher uptake of PCV was associated with larger declines in pneumonia mortality. This association did not differ by income level of the region in Brazil and Colombia. In Peru, low-income regions observed larger declines in pneumonia deaths, but there was large uncertainty in the difference between the low- and high-income regions. We estimated that, with 90% coverage, there would be 4-38% declines in all-cause pneumonia mortality across income levels and countries. Conclusions: Regions with higher PCV coverage experienced larger declines in pneumonia deaths, regardless of the income level. Having more reliable data on mortality records and vaccine uptake would improve the reliability of vaccine impact estimates. Copyright:
Background: Pneumococcal conjugate vaccines (PCVs) have prevented deaths due to pneumonia among children. The effect may differ between higher- and lower-income populations due to various factors, such as differences in the distribution of pneumococcal serotypes, healthcare access, and PCV uptake. This study aims to evaluate an association between increasing PCV coverage and population-level declines in death due to pneumonia and its variation by socioeconomic status of subnational regions. Methods: We analyzed municipality-level mortality data from 2005 and 2015 for children aged 2-23 months in Brazil, Colombia, and Peru. We fit Poisson regression models to estimate the relationship between changes in PCV uptake and deaths due to all-cause pneumonia among subnational regions with different income levels. We controlled for changes unrelated to PCV by using data on non-respiratory deaths over time. Results: Uptake of the third dose of PCV varied across subnational regions and was higher in high-income regions. Higher uptake of PCV was associated with larger declines in pneumonia mortality. This association did not differ by income level of the region in Brazil and Colombia. In Peru, low-income regions observed larger declines in pneumonia deaths, but there was large uncertainty in the difference between the low- and high-income regions. We estimated that, with 90% coverage, there would be 4-38% declines in all-cause pneumonia mortality across income levels and countries. Conclusions: Regions with higher PCV coverage experienced larger declines in pneumonia deaths, regardless of the income level. Having more reliable data on mortality records and vaccine uptake would improve the reliability of vaccine impact estimates. Copyright:
Authors: Sylvia Becker-Dreps; Erick Amaya; Lan Liu; Gilberto Moreno; Julio Rocha; Rafaela Briceño; Jorge Alemán; Michael G Hudgens; Christopher W Woods; David J Weber Journal: Pediatr Infect Dis J Date: 2014-06 Impact factor: 2.129
Authors: Victor Suarez; Fabiana Michel; Cristiana M Toscano; Ana Luiza Bierrenbach; Marco Gonzales; Airlane Pereira Alencar; Cuauhtemoc Ruiz Matus; Jon K Andrus; Lucia H de Oliveira Journal: Vaccine Date: 2016-08-09 Impact factor: 3.641
Authors: Janepsy Diaz; Solana Terrazas; Ana L Bierrenbach; Cristiana M Toscano; Gizelton P Alencar; Andrés Alvarez; Maria T Valenzuela; Jon Andrus; Roberto del Aguila; Juan C Hormazábal; Pamela Araya; Paola Pidal; Cuauhtemoc R Matus; Lucia H de Oliveira Journal: PLoS One Date: 2016-04-08 Impact factor: 3.240
Authors: Lucia H de Oliveira; Kayoko Shioda; Maria Tereza Valenzuela; Cara B Janusz; Analía Rearte; Alyssa N Sbarra; Joshua L Warren; Cristiana M Toscano; Daniel M Weinberger Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 9.079
Authors: Javier de-Miguel-Díez; Ana López-de-Andrés; Valentín Hernández-Barrera; José M de-Miguel-Yanes; David Carabantes-Alarcón; Zichen Ji; Jose J Zamorano-Leon; Rodrigo Jiménez-García Journal: Eur J Pediatr Date: 2022-04-25 Impact factor: 3.860
Authors: Jackie Kleynhans; Stefano Tempia; Kayoko Shioda; Anne von Gottberg; Daniel M Weinberger; Cheryl Cohen Journal: PLoS Med Date: 2021-02-16 Impact factor: 11.069